CLINICAL_TRIALS
trial_result
· 2024-02-05
Clinical Trial Update: Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme [Phase 2]
Summary
A Phase 2 clinical trial evaluating cabozantinib (XL184) in adults with glioblastoma multiforme has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Exelixis | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2024-02-05